Cargando…

Treatment selection with organoids in an EGFRm + TP53m stage IA1 patient with recurrence after radical surgery

Detalles Bibliográficos
Autores principales:	Yamauchi, Yoshikane, Saito, Yuichi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2022
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8987835/ https://www.ncbi.nlm.nih.gov/pubmed/35399248 http://dx.doi.org/10.21037/jtd-22-64

Ejemplares similares

First-line treatment selection with organoids of an EGFRm + TP53m stage IA1 patient with early metastatic recurrence after radical surgery and follow-up
por: Jia, Ziqi, et al.
Publicado: (2020)

TP53 R249S mutation in hepatic organoids captures the predisposing cancer risk
por: Lam, Yin Kau, et al.
Publicado: (2023)

Polycaprolactone Electrospun Scaffolds Produce an Enrichment of Lung Cancer Stem Cells in Sensitive and Resistant EGFRm Lung Adenocarcinoma
por: Polonio-Alcalá, Emma, et al.
Publicado: (2021)

Mitigating the Risk of t-MNs Development: TP53 or Not TP53?
por: Tesio, Melania
Publicado: (2023)

The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis
por: Leroy, Bernard, et al.
Publicado: (2013)

Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset
por: Ohe, Yuichiro, et al.
Publicado: (2018)

Savolitinib ± Osimertinib in Japanese Patients with Advanced Solid Malignancies or EGFRm NSCLC: Ph1b TATTON Part C
por: Yoh, Kiyotaka, et al.
Publicado: (2021)

Selection of Pathological N0 (pN0) in Clinical IA (cIA) Lung Adenocarcinoma by Imaging Findings of the Main Tumor
por: Kanamoto, Yasuyuki, et al.
Publicado: (2020)

Somatic intronic TP53 c.375+5G mutations are a recurrent but under‐recognized mode of TP53 inactivation
por: Chui, M Herman, et al.
Publicado: (2021)

TP53 and TP53-associated genes are correlated with the prognosis of paediatric neuroblastoma
por: Wang, Haiwei, et al.
Publicado: (2022)

TP53-PTEN-NF1 depletion in human brain organoids produces a glioma phenotype in vitro
por: Singh, Sanjay K., et al.
Publicado: (2023)

Recurrence risk factors in stage IA grade 1 endometrial cancer
por: Nwachukwu, Chika, et al.
Publicado: (2021)

Remote intracranial recurrence of IDH mutant gliomas is associated with TP53 mutations and an 8q gain
por: Nakae, Shunsuke, et al.
Publicado: (2017)

Optimisation of TP53 reporters by systematic dissection of synthetic TP53 response elements
por: Trauernicht, Max, et al.
Publicado: (2023)

CLPTM1L expression predicts recurrence of patients with intermediate‑ and high‑risk stage IB‑IIB cervical cancer undergoing radical hysterectomy followed by TP as adjuvant chemotherapy
por: Awazu, Yuichiro, et al.
Publicado: (2023)

Recurrence pattern and TP53 mutation in upper urinary tract urothelial carcinoma
por: Chen, Chung-Hsin, et al.
Publicado: (2016)

Prognostic factors for tumor recurrence in endometrioid endometrial cancer stages IA and IB
por: Han, Kyung Hee, et al.
Publicado: (2017)

The TP53 fertility network
por: Paskulin, Diego d’Avila, et al.
Publicado: (2012)

TP53: an oncogene in disguise
por: Soussi, T, et al.
Publicado: (2015)

TP53 in Myelodysplastic Syndromes
por: Jiang, Yan, et al.
Publicado: (2021)

Studies of TP53 haplotypes in relation to LOH and TP53 mutations in breast cancer patients
por: Langerød, A, et al.
Publicado: (2000)

Expression signature based on TP53 target genes doesn't predict response to TP53-MDM2 inhibitor in wild type TP53 tumors
por: Sonkin, Dmitriy
Publicado: (2015)

Expression of TP53 Isoforms p53β or p53γ Enhances Chemosensitivity in TP53(null) Cell Lines
por: Silden, Elisabeth, et al.
Publicado: (2013)

Nutlin‐3a selects for cells harbouring TP 53 mutations
por: Kucab, Jill E., et al.
Publicado: (2016)

Adjusted Indirect Comparison Using Propensity Score Matching of Osimertinib to Platinum-Based Doublet Chemotherapy in Patients with EGFRm T790M NSCLC Who Have Progressed after EGFR-TKI
por: Mann, Helen, et al.
Publicado: (2017)

Redox-sensitive TP53INP1 SUMOylation as an oxidative stress sensor to activate TP53
por: Bonacci, Thomas, et al.
Publicado: (2014)

TP53 Combined Phenotype Score Is Associated with the Clinical Outcome of TP53-Mutated Myelodysplastic Syndromes
por: Yabe, Mariko, et al.
Publicado: (2021)

TP53_PROF: a machine learning model to predict impact of missense mutations in TP53
por: Ben-Cohen, Gil, et al.
Publicado: (2022)

Predictive factors of recurrence after resection of subsolid clinical stage IA lung adenocarcinoma
por: Im, Dong Jin, et al.
Publicado: (2021)

MDM4 expression as an indicator of TP53 reactivation by combined targeting of MDM2 and MDM4 in cancer cells without TP53 mutation
por: Hirose, Mitsuaki, et al.
Publicado: (2014)

Updates from the TP53 universe
por: Pentimalli, Francesca
Publicado: (2018)

TP53 in Biology and Treatment of Osteosarcoma
por: Synoradzki, Kamil Jozef, et al.
Publicado: (2021)

The Role of TP53 in Adaptation and Evolution
por: Voskarides, Konstantinos, et al.
Publicado: (2023)

Significance of TP53 mutation in bladder cancer disease progression and drug selection
por: Wu, Guang, et al.
Publicado: (2019)

Selective pericentromeric heterochromatin dismantling caused by TP53 activation during senescence
por: Mendez-Bermudez, Aaron, et al.
Publicado: (2022)

Prognostic value genotypes and LOH at TP53 codon 72 and TP53 mutations in primary breast cancer
por: Kyndi, M, et al.
Publicado: (2005)

The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromes
por: McGraw, K L, et al.
Publicado: (2015)

Comprehensive Identification of Deleterious TP53 Missense VUS Variants Based on Their Impact on TP53 Structural Stability
por: Tam, Benjamin, et al.
Publicado: (2021)

TP53 inhibitor PFTα increases the sensitivity of arsenic trioxide in TP53 wildtype tumor cells
por: Wang, Haiwei, et al.
Publicado: (2022)

TP53 mutations in early-stage ovarian carcinoma, relation to long-term survival
por: Wang, Y, et al.
Publicado: (2004)

Cannot write session to /tmp/vufind_sessions/sess_mqtb43e5itbkbftt9b973soubs